Body
Studya | Population | Regimen | Efficacy (95% CI) |
Percentage of Participants with Detectable Plasma Levels of TFV |
---|---|---|---|---|
Partners PrEP (n = 4,758)1 |
Serodiscordant couples in Kenya and Uganda n = 1,579 randomized to receive TDF/FTC |
TDF/FTC | 75% (55% to 87%) | 82%b |
CDC TDF2 (n = 1,215)2 |
Heterosexual men and women in Botswana | TDF/FTC | 63% (22% to 83%) | 79% |
Fem-PrEP (n = 2,056)3 |
Heterosexual women in South Africa, Kenya, and Tanzania | TDF/FTC | No effect | 24% |
VOICE (n = 5,029)4 |
Heterosexual women in South Africa, Uganda, and Zimbabwe n = 1,003 randomized to receive TDF/FTC | TDF/FTC | No effect | 29% |
a The data in this table are from studies that included heterosexual women. b Among the patients who achieved detectable plasma levels of TFV, the efficacy estimate for daily TDF/FTC was 91% (95% CI, 47% to 98%).4 Key: CI = confidence interval; FTC = emtricitabine; PrEP = pre=exposure prophylaxis TDF = tenofovir disoproxil fumarate; TFV = tenofovir |